Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab
- Status
- UNKNOWN
- Phase
- NA
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
- Status
- COMPLETED
- Phase
- PHASE2
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab for Pulmonary Sarcoidosis
- Status
- COMPLETED
- Phase
- PHASE2
Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital
- Status
- COMPLETED
- Phase
- N/A
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- Status
- TERMINATED
- Phase
- PHASE2
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
- Status
- TERMINATED
- Phase
- PHASE2
Drug Intervention in Chronic Fatigue Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Treatment of Aggressive Localized Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2